A leader in nuclear technology obtains funding to produce medical isotopes in Europe and to help meet growing demands to provide diagnostic imaging for life-threatening diseases on a global scale.
SHINE Medical Technologies today announced the creation of a new division of the company — SHINE Therapeutics. The establishment of the division enhances the company’s ability to focus on filling critical future needs in the rapidly growing therapeutic isotope market, while continuing to leverage its radioisotope production expertise.
SHINE Medical Technologies, LLC today announced the appointment of Paul D. Ryan to the company’s board of directors.
SHINE and Phoenix tested the first production-ready accelerator in SHINE’s Janesville facility over the course of 5.5 days to determine percentage uptime and total neutron output. The average system neutron yield was measured to be 10% percent beyond the required output, with greater than 99 percent uptime.